Cargando…
Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer
The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revea...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397633/ https://www.ncbi.nlm.nih.gov/pubmed/34625422 http://dx.doi.org/10.1158/0008-5472.CAN-21-1159 |
_version_ | 1784772161048674304 |
---|---|
author | Mandigo, Amy C. Shafi, Ayesha A. McCann, Jennifer J. Yuan, Wei Laufer, Talya S. Bogdan, Denisa Gallagher, Lewis Dylgjeri, Emanuela Semenova, Galina Vasilevskaya, Irina A. Schiewer, Matthew J. McNair, Chris M. de Bono, Johann S. Knudsen, Karen E. |
author_facet | Mandigo, Amy C. Shafi, Ayesha A. McCann, Jennifer J. Yuan, Wei Laufer, Talya S. Bogdan, Denisa Gallagher, Lewis Dylgjeri, Emanuela Semenova, Galina Vasilevskaya, Irina A. Schiewer, Matthew J. McNair, Chris M. de Bono, Johann S. Knudsen, Karen E. |
author_sort | Mandigo, Amy C. |
collection | PubMed |
description | The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revealed unexpected repositioning and cooperation with oncogenic transcription factors, including the major driver of disease progression, the androgen receptor (AR). Further investigation revealed that observed AR/E2F1 cooperation elicited novel transcriptional networks that promote cancer phenotypes, especially as related to evasion of cell death. These observations were reflected in assessment of human disease, indicating the clinical relevance of the AR/E2F1 cooperome in prostate cancer. Together, these studies reveal new mechanisms by which RB loss induces cancer progression and highlight the importance of understanding the targets of E2F1 function. SIGNIFICANCE: This study identifies that RB loss in prostate cancer drives cooperation between AR and E2F1 as coregulators of transcription, which is linked to the progression of advanced disease. |
format | Online Article Text |
id | pubmed-9397633 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-93976332023-01-05 Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer Mandigo, Amy C. Shafi, Ayesha A. McCann, Jennifer J. Yuan, Wei Laufer, Talya S. Bogdan, Denisa Gallagher, Lewis Dylgjeri, Emanuela Semenova, Galina Vasilevskaya, Irina A. Schiewer, Matthew J. McNair, Chris M. de Bono, Johann S. Knudsen, Karen E. Cancer Res Molecular Cell Biology The retinoblastoma tumor suppressor (RB) is a critical regulator of E2F-dependent transcription, controlling a multitude of protumorigenic networks including but not limited to cell-cycle control. Here, genome-wide assessment of E2F1 function after RB loss in isogenic models of prostate cancer revealed unexpected repositioning and cooperation with oncogenic transcription factors, including the major driver of disease progression, the androgen receptor (AR). Further investigation revealed that observed AR/E2F1 cooperation elicited novel transcriptional networks that promote cancer phenotypes, especially as related to evasion of cell death. These observations were reflected in assessment of human disease, indicating the clinical relevance of the AR/E2F1 cooperome in prostate cancer. Together, these studies reveal new mechanisms by which RB loss induces cancer progression and highlight the importance of understanding the targets of E2F1 function. SIGNIFICANCE: This study identifies that RB loss in prostate cancer drives cooperation between AR and E2F1 as coregulators of transcription, which is linked to the progression of advanced disease. American Association for Cancer Research 2022-01-15 2021-10-08 /pmc/articles/PMC9397633/ /pubmed/34625422 http://dx.doi.org/10.1158/0008-5472.CAN-21-1159 Text en ©2021 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Molecular Cell Biology Mandigo, Amy C. Shafi, Ayesha A. McCann, Jennifer J. Yuan, Wei Laufer, Talya S. Bogdan, Denisa Gallagher, Lewis Dylgjeri, Emanuela Semenova, Galina Vasilevskaya, Irina A. Schiewer, Matthew J. McNair, Chris M. de Bono, Johann S. Knudsen, Karen E. Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer |
title | Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer |
title_full | Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer |
title_fullStr | Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer |
title_full_unstemmed | Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer |
title_short | Novel Oncogenic Transcription Factor Cooperation in RB-Deficient Cancer |
title_sort | novel oncogenic transcription factor cooperation in rb-deficient cancer |
topic | Molecular Cell Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9397633/ https://www.ncbi.nlm.nih.gov/pubmed/34625422 http://dx.doi.org/10.1158/0008-5472.CAN-21-1159 |
work_keys_str_mv | AT mandigoamyc noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT shafiayeshaa noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT mccannjenniferj noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT yuanwei noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT laufertalyas noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT bogdandenisa noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT gallagherlewis noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT dylgjeriemanuela noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT semenovagalina noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT vasilevskayairinaa noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT schiewermatthewj noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT mcnairchrism noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT debonojohanns noveloncogenictranscriptionfactorcooperationinrbdeficientcancer AT knudsenkarene noveloncogenictranscriptionfactorcooperationinrbdeficientcancer |